Stockwatch: The punctuations of life science investment
This article was originally published in Scrip
Executive Summary
As investors in the life sciences sector bask in the glow of another significant monthly return, it is clear that not even the Ukrainian crisis can dampen the advance of the biotech sector. There were some tense days last week when virtually all pharmaceutical and biotechnology stocks went down with the market (and those recent biotech IPOs moved down much more than most other stocks), but by the end of the week the bankers touting IPOs and secondary offerings had re-emerged from their bunkers, swapped their tin hats for their toupees and started to barrack investors again.